Abstract: The invention relates to a compound comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to a pharmaceutical formulation, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical formulation comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.

Abstract: The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.

Abstract: The present invention relates to a solid composition comprising a PYY compound and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.

Abstract: An electronic theft-preventing system, including a first and a second multi-axis magnetometer and configured to output first and second vector signals representing movement of first and second magnetic field vectors; and a signal processor receiving the first and second vector signals, and configured to determine a multi-dimensional transformation, in accordance with optimization of a difference between the second vector signal and a compensation signal; wherein the compensation signal is generated from a transformation of the first vector signal in accordance with the multi-dimensional transformation; and generate a compensated second vector signal from the second vector signal and the first compensation signal. Determining that a detector signal meets a predefined criterion; and in response to at least the determining that the detector signal meets the predefined criterion, raising or forgo raising an alarm that warns about a possible theft-related event.

Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: Provided is an oscillation absorber for a structure, particularly a wind power plant, with a pendulum that is attachable to a component of the structure and a damper for dampening the motion of the pendulum, in which the pendulum passes through a containment ring that limits the deflection of the pendulum, wherein the containment ring is attachable to at least one wall of the structure.

Abstract: The invention relates to PYY compounds with the amino acid modifications 7Lys, 30Trp, and 31Leu, and in addition to these, 22Ile and/or 28Tyr, and derivatives thereof. The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: Provided is an oscillation absorber for a structure, particularly a wind power plant, with a pendulum that is attachable to a component of the structure and a damper for dampening the motion of the pendulum, in which the pendulum passes through a containment ring that limits the deflection of the pendulum, wherein the containment ring is attachable to at least one wall of the structure.

Abstract: The invention relates to PYY compounds with the amino acid modifications 7Lys, 30Trp, and 31Leu, and in addition to these, 22Ile and/or 28Tyr, and derivatives thereof. The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: A wind turbine tower with an elevator system and a method to install the elevator system is provided. The tower for a wind turbine comprises includes an elevator system including guide wires. The guide wires are connected to a guide wire fixture arrangement. The tower includes a platform that is arranged in the area of the lower end of the tower. The platform comprises an opening to allow the guide wires to pass through the opening. The platform includes a connection means, to detachably connect the guide wire fixture arrangement to the platform during transportation and installation of the tower. The platform includes a hoist system to lower the guide wire fixture arrangement through the opening in the platform into a space below the tower to extend the guide wires through the opening in the platform.

Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: A wind turbine tower with an elevator system and a method to install the elevator system is provided. The tower for a wind turbine comprises includes an elevator system including guide wires. The guide wires are connected to a guide wire fixture arrangement. The tower includes a platform that is arranged in the area of the lower end of the tower. The platform comprises an opening to allow the guide wires to pass through the opening. The platform includes a connection means, to detachably connect the guide wire fixture arrangement to the platform during transportation and installation of the tower. The platform includes a hoist system to lower the guide wire fixture arrangement through the opening in the platform into a space below the tower to extend the guide wires through the opening in the platform.

Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogs thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.

Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Abstract: The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia.

Abstract: A flange assembly for a tower segment is provided. The flange assembly includes a number of flange portions each with a first interface to the tower segment and a second interface to connect to another flange portion. A production method for a flange is further provided.

Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.